title: Role of surgery in the treatment of ovarian metastases from colorectal cancer.
abstract: OBJECTIVE
  The role of surgical resection in the treatment of metastatic ovarian tumors originating from colorectal cancer (CRC) remains uncertain. We sought to identify a subgroup of patients who would benefit from surgical resection.
  
  
  METHODS
  We analyzed the clinicopathological and follow-up data on 34 patients who underwent surgical resection of metastatic ovarian tumors originating from CRC.
  
  
  RESULTS
  Synchronous ovarian metastasis was detected in 27 patients (79.4%) and metachronous metastasis in 7 (20.6%). The histologic type of the primary CRC was adenocarcinoma in 26 patients (76.5%), mucinous carcinoma in 7 (20.6%), and signet ring cell carcinoma in 1 (2.9%). Complete cytoreduction was possible in 11 patients (32.4%). The 3-year overall survival (OS) rate was 25.1%. The median OS time was 19 months (range, 2-64 months) in all patients, and 36 months (range, 10-64 months) in patients who underwent complete cytoreduction. Cox's proportional hazards analysis showed that unilateral ovarian metastasis (relative risk [RR], 0.405; 95% confidence interval [CI], 0.171-0.959) and metastasis confined to the pelvic cavity (RR, 0.165; 95% CI, 0.031-0.878) were significantly associated with favorable prognosis.
  
  
  CONCLUSIONS
  Surgical resection may be beneficial in selected patients with ovarian metastasis arising from CRC, when metastasis is limited to the pelvis.
authors.affiliation: Center for Colorectal Cancer, Research Institute & Hospital, National Cancer Center, Goyang, Korea.
authors.forename: Tae-Sung
authors.initials: TS
authors.lastname: Chung
authors.forename: Hee Jin
authors.initials: HJ
authors.lastname: Chang
authors.forename: Kyung Hae
authors.initials: KH
authors.lastname: Jung
authors.forename: Sang-Yoon
authors.initials: SY
authors.lastname: Park
authors.forename: Seok-Byung
authors.initials: SB
authors.lastname: Lim
authors.forename: Hyo Seong
authors.initials: HS
authors.lastname: Choi
authors.forename: Seung-Yong
authors.initials: SY
authors.lastname: Jeong
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000556:secondary / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000473:pathology / Q000556:secondary / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018279:Carcinoma, Signet Ring Cell / Q000473:pathology / Q000556:secondary / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000401:mortality* / Q000556:secondary / Q000601:surgery*; D010052:Ovariectomy; D010534:Peritoneal Neoplasms / Q000401:mortality / Q000556:secondary / Q000601:surgery; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D015996:Survival Rate